Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The company also has NVL-655, an ALK-selective inhibitor for ALK-driven NSCLC. Similar to Zidesamtinib, NLV-655 has brain penetrance, so it should minimize the negative effects on the CNS ...

Research presented at 2024’s American Society of Clinical Oncology (ASCO) conference indicated that a drug called lorlatinib showed significant progress in treating a type of advanced non-small cell ...

Neladalkib (NVL-665). Nuvalent’s next-most advanced asset is NVL-655, an oral, brain-penetrant anaplastic lymphoma kinase [ALK] inhibitor for the treatment of ALK+ NSCLC – which accounts for ...

in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Report pivotal data for tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small ...

Phosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in pancreatic cancer cells. Viability screening of 146 targeted drugs identified ATR ...

Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potenti Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy ...